Without effective biochemical control, indicated by normalized IGF-1 levels, patients with acromegaly face a range of disease-related comorbidities, with cardiovascular disease and malignancy being the main contributors of increased mortality [2]. This evidence concerns the gene IGF1 and acromegaly.